Dual immune check point blockade in MGMT-unmethylated newly diagnosed glioblastoma: NRG Oncology BN007, a randomized phase II/III clinical trial 2025

SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers 2025

PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19) 2024

Phase III randomized, placebo-controlled clinical trial of donepezil for treatment of cognitive impairment in breast cancer survivors after adjuvant chemotherapy (WF-97116) 2024

Effects of a geriatric assessment intervention on patient-reported symptomatic toxicity in older adults with advanced cancer 2023

A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45) 2022

Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216) 2022

Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) Trial 2021

Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131 2021

NSABP B-47/NRG Oncology Phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2 2020

Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003 2020

Randomized trial of lenalidomide versus observation in smoldering multiple myeloma 2020

Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient 2020

Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study 2019

Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial 2019

Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study 2018

Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102 2018

Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202 2018

Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology) 2017

E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group 2017

Intentional weight loss and endometrial cancer risk 2017

Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2 2017

Awareness of breast density and its impact on breast cancer detection and risk 2015

Diabetes, metformin, and breast cancer in postmenopausal women 2012

What a difference a letter can make 2012

Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ 2009

Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence 2009

Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer 2008

Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment 2007

Mammography surveillance and mortality in older breast cancer survivors 2007

Receipt of appropriate primary breast cancer therapy and adjuvant therapy are not associated with obesity in older women with access to health care 2007

Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy 2006

A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS) [abstract] 2024

Cannabis use for cancer-related symptoms in rural versus urban Minnesota [abstract] 2024

Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with Pembrolizumab: clinical update [abstract] 2024

A novel cannabis education clinic for patients with cancer: patient characteristics from initial visit [abstract] 2022

Self-reported efficacy and usage of cannabis among patients with cancer within the Minnesota Cannabis Program [abstract] 2022

Using machine learning to identify older adults at high risk for hospitalization and mortality via the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [abstract] 2020

Tumor characteristics and treatment in early-onset colorectal cancer [abstract] 2018

Medical scribes in a community oncology clinic [abstract] 2016

A randomized trial of vitamin D3 in aromatase inhibitor-associated musculoskeletal symptoms [abstract] 2015

Association between musculoskeletal symptoms and serum vitamin D levels in women receiving aromatase inhibitor treatment [abstract] 2013

Validation of genomic markers that predict distant recurrence risk via FISH assays in women with early stage breast carcinoma [abstract] 2007